Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium
15. September 2022 08:00 ET
|
Imbria Pharmaceuticals Inc.
BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022
22. August 2022 08:00 ET
|
Imbria Pharmaceuticals Inc.
BOSTON, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today...